Media stories about Krystal Biotech (NASDAQ:KRYS) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Krystal Biotech earned a news sentiment score of 0.03 on Accern’s scale. Accern also gave news coverage about the company an impact score of 44.2243255848193 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Separately, Ladenburg Thalmann Financial Services assumed coverage on Krystal Biotech in a research report on Wednesday, October 18th. They issued a “buy” rating and a $23.00 price target for the company.
Krystal Biotech (NASDAQ KRYS) opened at 9.90 on Wednesday. Krystal Biotech has a 52-week low of $9.01 and a 52-week high of $11.98. The company has a 50 day moving average price of $10.00 and a 200-day moving average price of $10.00. The firm’s market cap is $95.47 million.
In other news, Director Daniel Janney acquired 200,000 shares of the business’s stock in a transaction that occurred on Friday, September 22nd. The shares were bought at an average price of $10.00 per share, with a total value of $2,000,000.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, COO Suma Krishnan acquired 100,000 shares of the business’s stock in a transaction that occurred on Friday, September 22nd. The shares were purchased at an average cost of $10.00 per share, for a total transaction of $1,000,000.00. Following the acquisition, the chief operating officer now owns 1,935,249 shares in the company, valued at $19,352,490. The disclosure for this purchase can be found here.
COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Krystal Biotech (KRYS) Share Price” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.com-unik.info/2017/11/01/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-krystal-biotech-krys-share-price.html.
About Krystal Biotech
Krystal Biotech, Inc gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. The Company has developed a Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases.
What are top analysts saying about Krystal Biotech Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Krystal Biotech Inc. and related companies.